Teresa de Rojas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1316809/publications.pdf

Version: 2024-02-01

933447 752698 31 440 10 20 citations h-index g-index papers 32 32 32 803 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	COVIDâ€19 infection in children and adolescents with cancer in Madrid. Pediatric Blood and Cancer, 2020, 67, e28397.	1.5	99
2	Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. Cancer Medicine, 2017, 6, 2606-2624.	2.8	42
3	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. European Journal of Cancer, 2021, 157, 198-213.	2.8	34
4	ACCELERATE – Five years accelerating cancer drug development for children and adolescents. European Journal of Cancer, 2022, 166, 145-164.	2.8	28
5	Rare use of patient-reported outcomesÂin childhood cancer clinical trials – a systematic review of clinical trialÂregistries. European Journal of Cancer, 2021, 152, 90-99.	2.8	27
6	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. European Journal of Cancer, 2022, 160, 112-133.	2.8	24
7	Access to Clinical Trials for Adolescents and Young Adults With Cancer: A Meta-Research Analysis. JNCI Cancer Spectrum, 2019, 3, pkz057.	2.9	23
8	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	1.2	22
9	Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives. JCO Global Oncology, 2020, 6, 1264-1275.	1.8	14
10	Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. European Journal of Cancer, 2019, 114, 36-46.	2.8	12
11	EORTC SPECTAâ€AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. International Journal of Cancer, 2020, 147, 1180-1184.	5.1	11
12	Clinical research tools in pediatric oncology: challenges and opportunities. Cancer and Metastasis Reviews, 2020, 39, 149-160.	5.9	9
13	Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas. European Journal of Cancer, 2022, 173, 71-90.	2.8	9
14	Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. Journal of Neuro-Oncology, 2018, 137, 205-213.	2.9	8
15	Intercontinental collaboration in clinical trials for children and adolescents with cancerâ€"A systematic review by ACCELERATE. Cancer Medicine, 2021, 10, 8462-8474.	2.8	8
16	The First Step to Integrating Adapted Common Terminology Criteria for Adverse Events for Children. Journal of Clinical Oncology, 2016, 34, 2196-2197.	1.6	7
17	Mitochondrial Disease in Children: The Nephrologist's Perspective. JIMD Reports, 2017, 42, 61-70.	1.5	7
18	Patient-reported outcomes are under-utilised in evaluating supportive therapies in paediatric oncology – A systematic review of clinical trial registries. Critical Reviews in Oncology/Hematology, 2022, 176, 103755.	4.4	7

#	Article	IF	CITATIONS
19	Management and outcome of children with neuroendocrine tumors of the appendix in Spain: Is there room for improvement?. Clinical and Translational Oncology, 2017, 19, 1168-1172.	2.4	6
20	Infantile hemangiopericytoma leading to hypovolemic shock in a neonate. Pediatric Blood and Cancer, 2018, 65, e26950.	1.5	5
21	Outcome of childhood leukaemia survivors and necrosis of the femoral head treated with autologous mesenchymal stem cells. Clinical and Translational Oncology, 2018, 20, 584-590.	2.4	5
22	Fertility status among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: results of the 58 Late Adverse Effects study. Human Reproduction, 2021, 37, 44-53.	0.9	5
23	Lessons learnt from the medical and psychosocial evaluation of childhood acute lymphoblastic leukemia (ALL) survivors enrolled in EORTC Children Leukemia Group Trials between 1971 and 1998 and future perspectives for long-term outcome research. Journal of Cancer Policy, 2018, 15, 82-86.	1.4	4
24	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. Neuro-Oncology, 2018, 20, i72-i72.	1.2	4
25	Standardizing nursing degree curriculum structure in Spain: A mixed-methods study. Nurse Education Today, 2022, 112, 105360.	3.3	4
26	Autologous Cord Blood Cells Infusion as Salvage Therapy for Engraftment Failure After Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Pediatric Blood and Cancer, 2016, 63, 1495-1496.	1.5	2
27	IgAâ€Mediated Autoimmune Hemolytic Anemia: A Clinical Conundrum. Pediatric Blood and Cancer, 2016, 63, 754-754.	1.5	2
28	Tumor predisposition syndromes: The challenge of de novo mutations. Pediatric Blood and Cancer, 2018, 65, e26882.	1.5	2
29	Comment on: "Early advice on managing children with cancer during the COVIDâ€19 pandemic and a call for sharing experiencesâ€. Pediatric Blood and Cancer, 2020, 67, e28377.	1.5	2
30	Cystinuria in a patient with 19q12q13.1 deletion. CEN Case Reports, 2016, 5, 67-69.	0.9	1
31	Comment on: Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic. European Journal of Cancer, 2020, 140, 158-160.	2.8	1